Millennium Management’s Xenon Pharmaceuticals XENE Stock Holding History

Millennium Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.7M	Sell	201,785 -433,271	-68%	-$20M	﹤0.01%	2027
2025 Q4	$28.5M	Sell	635,056 -748,951	-54%	-$31.5M	0.01%	1230
2025 Q3	$55.6M	Buy	1,384,007 +501,172	+57%	+$17.7M	0.02%	792
2025 Q2	$27.6M	Buy	882,835 +648,779	+277%	+$21.2M	0.01%	1267
2025 Q1	$7.85M	Sell	234,056 -111,984	-32%	-$4.25M	﹤0.01%	2424
2024 Q4	$13.6M	Buy	346,040 +137,014	+66%	+$5.66M	0.01%	1876
2024 Q3	$8.23M	Buy	209,026 +33,442	+19%	+$1.35M	﹤0.01%	2374
2024 Q2	$6.85M	Buy	175,584 +91,923	+110%	+$3.67M	﹤0.01%	2420
2024 Q1	$3.6M	Buy	83,661 +6,696	+9%	+$308K	﹤0.01%	3209
2023 Q4	$3.55M	Sell	76,965 -18,528	-19%	-$655K	﹤0.01%	3095
2023 Q3	$3.26M	Sell	95,493 -117,845	-55%	-$4.41M	﹤0.01%	3122
2023 Q2	$8.21M	Sell	213,338 -8,132	-4%	-$323K	﹤0.01%	2212
2023 Q1	$7.93M	Sell	221,470 -373,071	-63%	-$13.8M	﹤0.01%	2187
2022 Q4	$23.4M	Buy	594,541 +34,192	+6%	+$1.25M	0.01%	1320
2022 Q3	$20.2M	Buy	560,349 +67,658	+14%	+$2.43M	0.01%	1333
2022 Q2	$15M	Buy	492,691 +356,365	+261%	+$10.8M	0.01%	1588
2022 Q1	$4.17M	Buy	136,326 +45,705	+50%	+$1.37M	﹤0.01%	3128
2021 Q4	$2.83M	Sell	90,621 -145,598	-62%	-$4.35M	﹤0.01%	3442
2021 Q3	$3.61M	Sell	236,219 -65,529	-22%	-$1.14M	﹤0.01%	3255
2021 Q2	$5.62M	Sell	301,748 -41,151	-12%	-$759K	﹤0.01%	2601
2021 Q1	$6.14M	Sell	342,899 -73,576	-18%	-$1.25M	﹤0.01%	2358
2020 Q4	$6.41M	Buy	416,475 +297,630	+250%	+$3.48M	﹤0.01%	2205
2020 Q3	$1.32K	Sell	118,845 -49,151	-29%	-$578K	﹤0.01%	2934
2020 Q2	$2.11M	Sell	167,996 -25,573	-13%	-$325K	﹤0.01%	2496
2020 Q1	$2.19M	Buy	193,569 +145,855	+306%	+$2.08M	﹤0.01%	1951
2019 Q4	$626K	Buy	+47,714	New	+$502K	﹤0.01%	3246
2019 Q2	–	Sell	-48,286	Closed	-$491K	–	4523
2019 Q1	$491K	Sell	48,286 -97,096	-67%	-$823K	﹤0.01%	3279
2018 Q4	$917K	Buy	145,382 +62,509	+75%	+$556K	﹤0.01%	2622
2018 Q3	$1.09M	Buy	+82,873	New	+$960K	﹤0.01%	2825
2017 Q1	–	Sell	-193,674	Closed	-$1.49M	–	3892
2016 Q4	$1.49M	Buy	+193,674	New	+$1.56M	﹤0.01%	2041

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management's XENE Position: Q1 2026 in Review

Millennium Management reduced its Xenon Pharmaceuticals (XENE) stake by 68% in Q1 2026, selling an estimated $20M and leaving 201,785 shares worth $11.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2027.

Millennium Management first reported a position in XENE in Q4 2016 and has held it in 30 quarters since. The position peaked at $55.6M in Q3 2025. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

Millennium Management held 201,785 shares of Xenon Pharmaceuticals worth $11.7M as of Q1 2026.
Millennium Management sold 433,271 Xenon Pharmaceuticals shares in Q1 2026, an estimated $20M.
Xenon Pharmaceuticals made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2027 holding.
Millennium Management first reported a position in Xenon Pharmaceuticals in Q4 2016 and has held it in 30 quarters since.
Millennium Management's Xenon Pharmaceuticals position peaked at $55.6M in Q3 2025.
290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.